ncRNA basic information
ncRNA ID:
MI0000070/MI0000115
ncRNA Database:
miRBase
ncRNA Name:
miR-16
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
BCL-2
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00853 (APRD00557)
Drug Name:
Temozolomide
Drug Method:
In present study, we first examined the sensitivity to temozolomide in six glioma cell lines, and established a resistant variant, U251MG/TR cells from TMZ-sensitive glioma cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251MG/TR and parental cells using cancer microRNA PCR Array. Among the downregulated microRNAs was miR-16, members of miR-15/16 family, whose expression was further validated by qRT-PCR in U251MG/TR and U251MG cells. The selective microRNA, miR-16 mimics or inhibitor was respectively transfected into U251MG/TR cells and AM38 cell. We found that treatment with the mimics of miR-16 greatly decreased the sensitivity of U251MG/TR cells to temozolomide, while sensitivity to these drugs was increased by treatment with the miR-16 inhibitor. In addition, the downregulation of miR-16 in temozolomide-sensitive AM38 cells was concurrent with the upregulation of Bcl-2 protein. Conversely, overexpression of miR-16 in temozolomide-resistant cells inhibited Bcl-2 expression and decreased temozolomide resistance.
Drug Response:
resistant
Cancer basic information
Cancer:
glioma
Tissue/Cell:
cell line (U-138MG, A172,LN382, AM-38, U-251MG, KMG4)
Other information
Title:
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Journal:
Int J Clin Exp Pathol
Published:
2015
PubMed ID:
26722459